We provide comprehensive, quantified, and flexible Target Safety Intelligence to assist toxicologists, informaticians, and drug discovery scientists in delivering safe and effective new treatments.
Location: United Kingdom
Total raised: $3.75M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 14.02.2026 | Seed | $3.75M | MMC Ventur... |
Mentions in press and media 5
| Date | Title | Description |
| 16.03.2026 | Ternary Therapeutics targets “undruggable” proteins with AI-designed molecular glues, raising €4.1 million | London-based BioTech startup Ternary Therapeutics has raised €4.1 million (£3.6 million) in Seed funding to scale an AI platform designed to create a new class of medicines known as molecular glues. The round was led by European venture fir... |
| 14.02.2026 | Sable Bio Raises $3.75 Million Seed To Scale Target Safety Assessment Platform | Sable Bio, a London-based AI startup focused on drug safety, has raised $3.75 million in seed funding to expand its platform that helps pharmaceutical companies identify safety risks earlier in drug discovery. The round was led by MMC Ventu... |
| 11.02.2026 | UK AI drug safety startup Sable Bio raises €3.15 million; plans to grow its London team | Sable Bio, a London-based AI drug safety startup, today announced that it has raised €3.2 million in Seed funding to scale its platform. The round was led by MMC Ventures, with participation from existing investors Episode 1 Ventures and Se... |
| - | sable bio | “We provide comprehensive, quantified, and flexible Target Safety Intelligence to assist toxicologists, informaticians, and drug discovery scientists in delivering safe and effective new treatments.” |
| - | sable bio | “We reinvent drug safety through cutting-edge AI-driven data and predictive analytics. Empowering researchers with state-of-the-art tools that integrate and expand on multimodal evidence, we propel the development of safe and effective medi... |